Vipulkumar Kantibhai Patel
GlaxoSmithKline
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Vipulkumar Kantibhai Patel.
Bioorganic & Medicinal Chemistry Letters | 2011
John Liddle; Francis Louis Atkinson; Michael David Barker; Paul S. Carter; Neil R. Curtis; Robert P. Davis; Clement Douault; Marion C. Dickson; Dorothy Elwes; Neil Stuart Garton; Matthew Gray; Thomas G. Hayhow; Clare I. Hobbs; Emma Jones; Stuart G. Leach; Karen Leavens; Huw D. Lewis; Scott McCleary; Margarete Neu; Vipulkumar Kantibhai Patel; Alex G.S. Preston; Cesar Ramirez-Molina; Tracy Jane Shipley; Philip Alan Skone; Nick Smithers; Donald O. Somers; Ann Louise Walker; Robert J. Watson; Gordon G. Weingarten
The lead optimisation of the diaminopyrimidine carboxamide series of spleen tyrosine kinase inhibitors is described. The medicinal chemistry strategy was focused on optimising the human whole blood activity whilst achieving a sufficient margin over liability kinases and hERG activity. GSK143 is a potent and highly selective SYK inhibitor showing good efficacy in the rat Arthus model.
Journal of Medicinal Chemistry | 2009
Nicola Mary Aston; Paul Bamborough; Jacqueline B. Buckton; Chris D. Edwards; Duncan S. Holmes; Katherine Louise Jones; Vipulkumar Kantibhai Patel; Penny A. Smee; Donald O. Somers; Giovanni Vitulli; Ann Louise Walker
p38alpha MAP kinase is a key anti-inflammatory target for rheumatoid arthritis, influencing biosynthesis of pro-inflammatory cytokines TNFalpha and IL-1beta at a translational and transcriptional level. In this paper, we describe how we have optimized a series of novel p38alpha/beta inhibitors using crystal structures of our inhibitors bound to p38alpha, classical medicinal chemistry, and modeling of virtual libraries to derive a molecule suitable for progression into clinical development.
Journal of Medicinal Chemistry | 2016
Alison Jo-Anne Woolford; Joseph E. Pero; Sridhar Aravapalli; Valerio Berdini; Joseph E. Coyle; Philip J. Day; Andrew M. Dodson; Pascal Grondin; Finn P. Holding; Lydia Y. W. Lee; Peng Li; Eric S. Manas; Joseph P. Marino; Agnes C. L. Martin; Brent W. Mccleland; Rachel McMenamin; Christopher W. Murray; Christopher E. Neipp; Lee W. Page; Vipulkumar Kantibhai Patel; Florent Potvain; Sharna J. Rich; Ralph A. Rivero; Kirsten S. Smith; Donald O. Somers; Lionel Trottet; Ranganadh Velagaleti; Glyn Williams; Ren Xie
Elevated levels of human lipoprotein-associated phospholipase A2 (Lp-PLA2) are associated with cardiovascular disease and dementia. A fragment screen was conducted against Lp-PLA2 in order to identify novel inhibitors. Multiple fragment hits were observed in different regions of the active site, including some hits that bound in a pocket created by movement of a protein side chain (approximately 13 Å from the catalytic residue Ser273). Using structure guided design, we optimized a fragment that bound in this pocket to generate a novel low nanomolar chemotype, which did not interact with the catalytic residues.
ACS Medicinal Chemistry Letters | 2017
Nicholas Measom; Kenneth David Down; David J. Hirst; Craig Jamieson; Eric S. Manas; Vipulkumar Kantibhai Patel; Donald O. Somers
We describe the incorporation of a bicyclo[1.1.1]pentane moiety within two known LpPLA2 inhibitors to act as bioisosteric phenyl replacements. An efficient synthesis to the target compounds was enabled with a dichlorocarbene insertion into a bicyclo[1.1.0]butane system being the key transformation. Potency, physicochemical, and X-ray crystallographic data were obtained to compare the known inhibitors to their bioisosteric counterparts, which showed the isostere was well tolerated and positively impacted on the physicochemical profile.
Drug Discovery Today | 2013
M. Jonathan Fray; Simon J. F. Macdonald; Ian Robert Baldwin; Nicholas Paul Barton; Jack A. Brown; Ian B. Campbell; Ian Churcher; Diane Mary Coe; Anthony William James Cooper; Andrew P. Craven; Gail Fisher; Graham G. A. Inglis; Henry A. Kelly; John Liddle; Aoife C. Maxwell; Vipulkumar Kantibhai Patel; Stephen Swanson; Natalie Wellaway
In this article, we describe a practical drug discovery project for third-year undergraduates. No previous knowledge of medicinal chemistry is assumed. Initial lecture workshops cover the basic principles; then students, in teams, seek to improve the profile of a weakly potent, insoluble phosphatidylinositide 3-kinase delta (PI3Kδ) inhibitor (1) through compound array design, molecular modelling, screening data analysis and the synthesis of target compounds in the laboratory. The project benefits from significant industrial support, including lectures, student mentoring and consumables. The aim is to make the learning experience as close as possible to real-life industrial situations. In total, 48 target compounds were prepared, the best of which (5b, 5j, 6b and 6ap) improved the potency and aqueous solubility of the lead compound (1) by 100-1000 fold and ≥tenfold, respectively.
Chemistry: A European Journal | 2013
David Orr; Alexandra Tolfrey; Jonathan M. Percy; Joanna Frieman; Zoe Alicia Harrison; Matthew Howard James Campbell-Crawford; Vipulkumar Kantibhai Patel
The direct microwave-mediated condensation between 3-oxetanone and primary amides and thioamides has delivered moderate to good yields of (hydroxymethyl)oxazoles and (hydroxymethyl)thiazoles. The reactions use a sustainable solvent and only require short reaction times. These are highly competitive methods for the construction of two classes of valuable heteroarenes, which bear a useful locus for further elaboration. Electronic structure calculations have shown that the order of events involves chalcogen atom attack at sp(3) carbon and alkyl-oxygen cleavage. The critical role of acid catalysis was shown clearly, and the importance of acid strength was demonstrated. The calculated barriers were also fully consistent with the observed order of thioamide and amide reactivity. Spontaneous ring opening involves a modest degree of C-O cleavage, moderating the extent of strain relief. On the acid-catalysed pathway, C-O cleavage is less extensive still, but proton transfer to the nucleofuge is well advanced with the carboxylic acid catalysts, and essentially complete with methanesulfonic acid.
Organic Letters | 2017
Thomas Aidan Clohessy; Alastair Roberts; Eric S. Manas; Vipulkumar Kantibhai Patel; Niall Andrew Anderson; Allan J. B. Watson
Functionalized bicyclic amino-azaheterocycles are rapidly accessed in a one-pot cross-coupling/reduction sequence enabled by the use of COware. Incompatible reagents are physically separated in a single reaction vessel to effect two chemoselective transformations-Suzuki-Miyaura cross-coupling and heteroarene reduction. The developed method allows access to novel heterocyclic templates, including semisaturated Hedgehog and dual PI3K/mTOR inhibitors, which show enhanced physicochemical properties compared to their unsaturated counterparts.
Archive | 2006
Rachael Ann Stevenage Ancliff; Francis Louis Atkinson; Michael David GlaxoSmithKl Barker; Philip Charles Box; Carla Daniel; Paul Martin Gore; Stephen Barry Guntrip; Masaichi Hasegawa; Graham George Adam Inglis; Kazuya Kano; Yasushi Miyazaki; Vipulkumar Kantibhai Patel; Timothy John Ritchie; Stephen Swanson; Ann Louise Walker; Christopher Roland Wellaway; Michael D. Woodrow
Bioorganic & Medicinal Chemistry Letters | 2007
Paul Bamborough; Richard Martyn Angell; Inder Bhamra; David W. Brown; James A. Bull; John A. Christopher; Anthony William James Cooper; Lynsey H. Fazal; Ilaria Giordano; Lucy Hind; Vipulkumar Kantibhai Patel; Lisa E. Ranshaw; Martin J. Sims; Philip Alan Skone; Kathryn J. Smith; Emma Vickerstaff; Melanie Washington
Archive | 2005
Paul Bamborough; Sebastien Andre Campos; Vipulkumar Kantibhai Patel; Stephen Swanson; Ann Louise Walker